On Tuesday, Piper Sandler maintained its Neutral rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00.
The stance comes in light of recent developments from Astellas Pharma Inc. (TSE:TYO:4503), which encountered a setback when the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) concerning an extended dosing schedule for the drug Izervay.
The unexpected FDA decision is seen as potentially beneficial for Apellis Pharmaceuticals, particularly regarding its product Syfovre. The market had anticipated approval for the sNDA that would have removed a 12-month usage restriction on Izervay. With the restriction remaining in place, Apellis' Syfovre may continue to have a competitive edge in the market.
The CRL from the FDA is believed to revolve around labeling issues, which suggests the possibility of a straightforward resolution. Despite the setback, Astellas might consider implementing an aggressive free drug sample campaign to keep patients on Izervay once they reach the 12-month limit, especially if the issue is expected to be resolved in the short term.
Piper Sandler's analysis indicates that the FDA's decision could provide an advantage to Apellis in the near term. The firm's reiteration of the Neutral rating and price target reflects their current assessment of Apellis Pharmaceuticals' market position and the potential impact of the FDA's recent action on its competitor's product.
In other recent news, Apellis Pharmaceuticals has been the subject of discussion following the release of its third-quarter 2024 results. The company experienced a 7% quarter-over-quarter increase in commercial vial demand for SYFOVRE, leading to net product revenues of $152 million. Despite a slight revenue decrease from the previous quarter, the firm remains optimistic about SYFOVRE's market potential.
Apellis also reported positive Phase III results for EMPAVELI in treating C3 glomerulopathy and immunoglobulin M-associated membranoproliferative glomerulonephritis. The company is preparing to file a supplemental NDA with the FDA for EMPAVELI and anticipates low single-digit percentage vial growth for the remainder of the year.
However, Baird has adjusted its outlook on Apellis Pharmaceuticals, reducing the price target to $55 from $92 while maintaining an Outperform rating on the stock. The firm attributes this adjustment to a lower net price and heightened competition in the market, but remains optimistic about the potential of Apellis Pharmaceuticals.
Lastly, the company aims to achieve operational breakeven, with a net cash burn of about $10 million, and reported a net loss of $57.4 million for Q3 2024. These are the recent developments for Apellis Pharmaceuticals.
InvestingPro Insights
Recent InvestingPro data provides additional context to Apellis Pharmaceuticals' (NASDAQ:APLS) market position. The company's market capitalization stands at $3.26 billion, reflecting its significant presence in the pharmaceutical sector. Despite the potential competitive advantage highlighted in the article, APLS has experienced a substantial 10.53% decline in its stock price over the past week, and a more concerning 56.26% drop year-to-date.
InvestingPro Tips suggest that while analysts anticipate sales growth for Apellis in the current year, the company is not expected to be profitable. This aligns with the reported operating income of -$223.33 million over the last twelve months. However, it's worth noting that Apellis operates with a moderate level of debt and its liquid assets exceed short-term obligations, which could provide financial flexibility as it navigates market challenges and potential opportunities arising from competitors' setbacks.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Apellis Pharmaceuticals, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.